title: The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients.
abstract: Our aim was to determine whether the HLA-Cw6 and late-cornified envelope (LCE) deletion polymorphisms were related to disease improvement among psoriasis patients treated with anti-tumor necrosis factor (TNF) antibodies. The study included a total of 116 patients. Positive response (68%) was defined as a reduction of at least 75% of the Psoriasis Area and Severity Index (PASI) after 24 weeks of starting the anti-TNF therapy. We found a trend toward a better response among Cw6-positive patients. The frequency of patients who did not reach the PASI75 was higher among the LCE-DD patients (P=0.028; odds ratio=2.45, 95% confidence interval=1.09-5.52). Patients who were Cw6-positive and LCE-I carriers (ID/II) were significantly more likely to reach PASI75 than those who were Cw6-negative and LCE-DD (P=0.034; odds ratio=3.14, 95% confidence interval=1.07-9.24). In conclusion, we found an interaction between the HLA-Cw6 and LCE genotypes on disease improvement among psoriatic patients treated with anti-TNFs.
authors: aDermatology II bMolecular Genetics cRheumatology, Hospital Universitario Central Asturias dDepartment of Medicine, University of Oviedo, Oviedo, Spain.
authors: Ana
authors: A
authors: Batalla
authors: Eliecer
authors: E
authors: Coto
authors: Daniel
authors: D
authors: González-Fernández
authors: Leire
authors: L
authors: González-Lara
authors: Juan
authors: J
authors: Gómez
authors: Jorge
authors: J
authors: Santos-Juanes
authors: Rubén
authors: R
authors: Queiro
authors: Pablo
authors: P
authors: Coto-Segura
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000235:genetics; D055233:Cornified Envelope Proline-Rich Proteins / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D015236:HLA-C Antigens / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D017384:Sequence Deletion; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D055233:Cornified Envelope Proline-Rich Proteins; D015236:HLA-C Antigens; C528994:HLA-C*06 antigen; C524765:LCE1B protein, human; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha